Moreover, Liu et al. (2019) have shown that crizotinib, in combination with cisplatin, can induce immunogenic cell death in NSCLC, as evidenced by surface exposure of calreticulin and extracellular release of ATP. Here, CALR is linked to non-small cell lung carcinoma.